Stroke with atrial fibrillation or atrial flutter: a descriptive population-based study from the Brest stroke registry

BMC Geriatrics

Armelle Gentric¹  Anne Tirel-Badets³  Irina Viakhireva-Dovganyuk³  François-Mathias Merrien³  Philippe Goas³  François Rouhart³  Emmanuel Nowak²  Serge Timsit³  Virginie Jannou³ 

[1] Department of Internal Medicine and Geriatrics, University Hospital of Brest, Boulevard Tanguy Prigent, Brest, 29200, Bretagne, France;University Hospital of Brest, CIC INSERM, Boulevard Tanguy Prigent, Brest, 29200, Bretagne, France;Neurology and Stroke Department, University Hospital of Brest, Boulevard Tanguy Prigent, Brest, 29200, Bretagne, France

关键词: Registry;    Anticoagulation;    CHADS2;    Atrial fibrillation;    Stroke;   

Others  :  1217697
DOI  :  10.1186/s12877-015-0067-3

 received in 2015-01-06, accepted in 2015-05-29,  发布年份 2015

【 摘 要 】

Background

In the 1990s, epidemiological studies estimated the prevalence of stroke caused by atrial fibrillation (AF) at about 15 %. Given the aging population, there is a rise in the number of AF patients. AF prevention guidelines based on clinical practice and the literature have been published and updated since 2001. Implementation seems to have an impact on the prescription of vitamin K antagonist (VKA). During the last 20 years, few population-based studies have focused on the prevalence of atrial arrhythmia (AA) in patients with stroke. The objective of the present prospective study, using data from 2008, was to evaluate the prevalence of AA (atrial fibrillation/flutter) in patients with stroke and the impact of implementing AF guidelines.

Methods

The prevalence of AA was studied in patients diagnosed with stroke from January 1 to December 31, 2008 in the population-based Stroke Registry of Brest, France (total population, 363,760 according to the 2008 census, with 295,553 aged 15 years or older). Guidelines implementation was assessed in terms of antithrombotic therapy (VKA, antiplatelet agent, none), and the CHADS2 (

C

ongestive heart failure,

H

ypertension,

A

ge > 75 years,

D

iabetes mellitus, and prior

S

troke or transient ischemic attack).

Results

851 cases of stroke were identified. The prevalence of AA was 31.7 % (n = 264), and increased with age from < 20 % in patients aged 45 to 54 years to nearly 50 % in patients ≥ 85 years. In patients with AA, 231 strokes were ischemic, 28 hemorrhagic and 5 undetermined. At time of stroke, AA was known in 207 patients (78.4 %). 54 of the 152 patients with CHADS2 score ≥ 2 (35.5 %) were treated with VKA; this proportion decreased with age: 50 % between 50 and 74 years, 43.8 % between 75 and 84 years, and 25 % at 85 years and older.

Conclusion

The prevalence of AA in the population-based Brest Stroke Registry in 2008 was higher than that reported by studies conducted 20 years ago. Despite publication of AF prevention guidelines, VKA prescription and use in elderly patients were significantly low.

【 授权许可】

   
2015 Jannou et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al.: Prevalence of diagnosed atrial fibrillation in adults. JAMA J Am Med Assoc 2001, 285:2370-5.
• [2]Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al.: Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997, 96:2455-61.
• [3]Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy TE: The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 1995, 98:476-84.
• [4]Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al.: Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham heart study. Circulation 2003, 107:2920-5.
• [5]Kwok CS, Loke YK, Hale R, Potter JF, Myint PK: Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology 2011, 76:914-22.
• [6]Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991, 22:983-8.
• [7]Gattellari M, Goumas C, Aitken R, Worthington JM: Outcomes for patients with ischaemic stroke and atrial fibrillation: the PRISM study (a program of research informing stroke management). Cerebrovasc Dis Basel Switz 2011, 32:370-82.
• [8]Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW: On behalf of the stroke prevention in atrial fibrillation (SPAF) investigators: factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I–III clinical trials. Stroke 1999, 30:1223-9.
• [9]Hart RG, Benavente O: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999, 131:492-501.
• [10]Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients Who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-67.
• [11]Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. Circulation 2001, 104:2118-50.
• [12]Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al.: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation -executive summary. Eur Heart J 2006, 27:1979-2030.
• [13]Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al.: Guidelines for the management of atrial fibrillation the task force for the management of atrial fibrillation of the european society of cardiology (ESC). Eur Heart J 2010, 31:2369-429.
• [14]Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH: Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010, 123:638-45.
• [15]O’Donnell M, Oczkowski W, Fang J, Kearon C, Silva J, Bradley C, et al.: Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol 2006, 5:749-54.
• [16]Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE: Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999, 131:927-34.
• [17]Biblo LA, Yuan Z, Quan KJ, Mackall JA, Rimm AA: Risk of stroke in patients with atrial flutter. Am J Cardiol 2001, 87:346-9.
• [18]Sandercock P, Bamford J, Dennis M, Burn J, Slattery J, Jones L, et al.: Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project). BMJ 1992, 305:1460-5.
• [19]Timsit S, Nowak E, Rouhart F, Goas P, Merrien FM, Tirel-Badets A, et al.: High completeness of the Brest stroke registry evidenced by analysis of sources and capture-recapture method. Neuroepidemiology 2014, 42:186-95.
• [20]Hatano S: Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976, 54:541-53.
• [21]Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981–1986. 2. Incidence, case fatality and overall outcome at one year of cerebral infarction, primary intracerebral haemorrhage and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 1990, 53:16-22.
• [22]Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al.: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke J Cereb Circ 1993, 24:35-41.
• [23]Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ: An evidence based causative classification system for acute ischemic stroke. Ann Neurol 2005, 58:688-97.
• [24]Ay H, Benner T, Murat Arsava E, Furie KL, Singhal AB, Jensen MB, et al.: A computerized algorithm for etiologic classification of ischemic stroke: the causative classification of stroke system. Stroke 2007, 38:2979-84.
• [25]Béjot Y, Ben Salem D, Osseby GV, Couvreur G, Durier J, Marie C, et al.: Epidemiology of ischemic stroke from atrial fibrillation in Dijon, France, from 1985 to 2006. Neurology 2009, 72:346-53.
• [26]Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al.: Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005, 36:1115-9.
• [27]Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A, Moore A, et al.: Stroke associated with atrial fibrillation–incidence and early outcomes in the North Dublin population stroke study. Cerebrovasc Dis Basel Switz 2010, 29:43-9.
• [28]WHO: World Health Day 2012, Are you ready? What you need to know about ageing [http://www.who.int/world-health-day/2012/toolkit/background/en/]
• [29]Lamassa M, Di Carlo A, Pracucci G, Basile AM, Trefoloni G, Vanni P, et al.: Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (the european community stroke project). Stroke J Cereb Circ 2001, 32:392-8.
• [30]Haeusler KG, Konieczny M, Endres M, Villringer A, Heuschmann PU: Impact of anticoagulation before stroke on stroke severity and long-term survival. Int J Stroke 2012, 7:544-50.
• [31]Indredavik B, Rohweder G, Lydersen S: Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation. J Intern Med 2005, 258:133-44.
• [32]Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al.: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003, 349:1019-26.
• [33]Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al.: Atrial fibrillation management: a prospective survey in ESC member countries. The euro heart survey on atrial fibrillation. Eur Heart J 2005, 26:2422-34.
• [34]Flaker GC, Pogue J, Yusuf S, Pfeffer MA, Goldhaber SZ, Granger CB, et al.: Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010, 3:277-83.
• [35]Hylek EM, D’Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S: Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke J Cereb Circ 2006, 37:1075-80.
• [36]Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, et al.: Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised controlled trial. Lancet 2007, 370:493-503.
• [37]Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al.: Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008, 1:84-91.
• [38]Sinnaeve PR, Brueckmann M, Clemens A, Oldgren J, Eikelboom J, Healey JS: Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. J Intern Med 2012, 271:15-24.
• [39]Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines (CPG): 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–47.